MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET

Company Participants

Matt Notarianni – Head-Investor Relations

Todd Newton – Interim Chief Executive Officer

Pete Carlson – Chief Financial Officer

Rohit Kashyap – President-Wound and Surgical

Robert Stein – President-Regenerative Medicine

Conference Call Participants

Anthony Petrone – Mizuho Group

RK – H.C. Wainwright

Carl Byrnes – Northland Capital

John Vandermosten – Zacks

Operator

Good afternoon and thank you for standing by. Welcome to the MiMedx Third Quarter 2022 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host today, Mr. Matt Notarianni, Head of Investor Relations for MiMedx. Thank you. You may begin.

Matt Notarianni

Thank you, Latonya, and good afternoon everyone. Welcome to the MiMedx third quarter 2022 operating and financial results conference call. With me on today's call are Interim Chief Executive Officer, Todd Newton; Chief Financial Officer, Pete Carlson; President, Wound and Surgical, Dr. Rohit Kashyap; and President, Regenerative Medicine, Dr. Robert Stein. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at mimedx.com. Todd and Pete will provide a summary of our operating highlights and financial results for the quarter and Todd will conclude with some remarks about our micronized dHACM Knee Osteoarthritis clinical trial program. At the conclusion of these remarks, Todd, Pete, Dr. Kashyap and Dr. Stein will be available for your questions.

Before we begin, I would like to remind you that our comments today will include forward-looking statements, including statements regarding future sales growth, future margin, expected market sizes for our products and potential time lines for clinical trials and FDA submissions and reviews. These expectations are subject to risks and uncertainties, and actual results may differ materially from those anticipated due to many factors. Actual results, market sizes, timing and FDA review will depend on a number of factors, including competition, access to customers, unforeseen circumstances and delays, the results of our clinical trials, our interpretation of those results and other factors. Additional factors that could impact outcomes and our results include those described in the Risk Factors section of our annual report on Form 10-K and our quarterly reports on Form 10-Q. Also, our comments today include non-GAAP financial measures and we provide a reconciliation to GAAP measures in our press release, which is available on our website at www.mimedx.com.